| PUBCHEM ID |
71307090
|
| UNII |
023Z5BR09K
|
| Preferred Term |
CEFTRIAXONE SODIUM
|
| CAS |
104376-79-6
|
| INCHIKEY |
PMRZKYOXTPBIQF-MAODNAKNSA-J
|
| Download |
mol2, pdbqt
|
| mol2 |
|
| Smiles |
CN(C(SCC(CS[C@H]1[C@H]2NC(/C(/c3csc(N)n3)=N\OC)=O)=C(C(O)=O)N1C2=O)=NC1=O)NC1=O
|
| Total Surface Area |
365,48
|
| Relative PSA |
0,60994
|
| TPSA |
287,82
|
| cLogS |
-2,953
|
| MW |
554,588
|
| cLogP |
-3,0111
|
| H-Acceptors |
15
|
| H-Donors |
4
|
| Ro5 violations |
2
|
| Druglikeness |
16,694
|
| DrugScore |
0,632458476138749
|
| Mutagenic |
none
|
| Tumorigenic |
none
|
| Reproductive Effective |
none
|
| Irritant |
none
|
| Blood-Brain Barrier |
BBB-
|
| Human Intestinal Absorption |
HIA-
|
| Caco-2 Permeability I |
Caco2-
|
| Caco-2 Permeability II |
-0,7547
|
| P-glycoprotein Substrate |
Substrate
|
| P-glycoprotein Inhibitor I |
Non-inhibitor
|
| P-glycoprotein Inhibitor II |
Inhibitor
|
| Renal Organic Cation Transporter |
Non-inhibitor
|
| Subcellular localization |
Mitochondria
|
| CYP450 2C9 Substrate |
Non-substrate
|
| CYP450 2D6 Substrate |
Non-substrate
|
| CYP450 3A4 Substrate |
Substrate
|
| CYP450 1A2 Inhibitor |
Non-inhibitor
|
| CYP450 2C9 Inhibitor |
Non-inhibitor
|
| CYP450 2D6 Inhibitor |
Non-inhibitor
|
| CYP450 2C19 Inhibitor |
Non-inhibitor
|
| CYP450 3A4 Inhibitor |
Inhibitor
|
| CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
| Human Ether-a-go-go-Related Gene Inhibition I |
Weak inhibitor
|
| Human Ether-a-go-go-Related Gene Inhibition II |
Non-inhibitor
|
| AMES Toxicity |
Non AMES toxic
|
| Carcinogens |
Non-carcinogens
|
| Fish Toxicity I |
High FHMT
|
| Fish Toxicity II |
1,2811
|
| Tetrahymena Pyriformis Toxicity I |
High TPT
|
| Tetrahymena Pyriformis Toxicity II |
0,5949
|
| Tetrahymena Pyriformis Toxicity |
Low HBT
|
| Biodegradation |
Not ready biodegradable
|
| Acute Oral Toxicity |
III
|
| Rat Acute Toxicity |
2,1681
|
| Carcinogenicity (Three-class) |
Non-required
|
